You are here

VX-222

Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR)

Yahoo/BusinessWire

Sat, 11/5/11 - 02:48 pm

Vertex Pharmaceuticals

Vertex 4-drug hepatitis C combo shows promise

Reuters

Wed, 07/27/11 - 10:40 am

Vertex Pharmaceuticals

pegylated interferon

Positive Data for Vertex HCV Drug

Yahoo/Zacks

Sat, 04/2/11 - 10:23 am

Vertex Pharmaceuticals

Vertex Pharmaceuticals' potential hepatitis C treatment meets safety goal in midstage study

Yahoo/AP

Thu, 03/31/11 - 12:27 pm

Vertex Pharmaceuticals